Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual ... Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0575 | 1.51315789474 | 3.8 | 4 | 3.6 | 8318 | 3.78530982 | CS |
4 | -0.1825 | -4.51732673267 | 4.04 | 4.34 | 3.6 | 7430 | 3.86900288 | CS |
12 | -0.3625 | -8.59004739336 | 4.22 | 5.2 | 2.78 | 13848 | 3.77215991 | CS |
26 | -0.0825 | -2.09390862944 | 3.94 | 5.2 | 2.78 | 9206 | 3.87206132 | CS |
52 | -1.9125 | -33.1455805893 | 5.77 | 5.93 | 2.78 | 6975 | 3.85686578 | CS |
156 | -19.5425 | -83.514957265 | 23.4 | 23.7 | 2.40101 | 86123 | 12.41987378 | CS |
260 | -10.5425 | -73.2118055556 | 14.4 | 58.5 | 2.40101 | 865528 | 27.31713226 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.